4109

Jia Jie BiomedicalTPEX:4109 Stock Report

Market Cap

NT$1.2b

7D

1.1%

1Y

-11.7%

Updated

18 Sep, 2021

Data

Company Financials
4109 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

4109 Overview

Jia Jie Biomedical Co., Ltd. engages in the soft-shelled turtle food processing, manufacturing, sales, and trading business.

Share Price & News

How has Jia Jie Biomedical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4109 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: 4109's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

1.1%

4109

-1.3%

TW Personal Products

-1.1%

TW Market


1 Year Return

-11.7%

4109

-17.0%

TW Personal Products

33.6%

TW Market

Return vs Industry: 4109 exceeded the TW Personal Products industry which returned -17% over the past year.

Return vs Market: 4109 underperformed the TW Market which returned 33.6% over the past year.


Shareholder returns

4109IndustryMarket
7 Day1.1%-1.3%-1.1%
30 Day-1.1%-0.3%5.5%
90 Day-6.7%-4.1%-0.1%
1 Year-11.7%-11.7%-14.6%-17.0%37.5%33.6%
3 Year-9.3%-9.3%-7.3%-15.7%75.3%57.3%
5 Year-42.8%-43.0%13.8%-1.4%120.9%83.9%

Long-Term Price Volatility Vs. Market

How volatile is Jia Jie Biomedical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Jia Jie Biomedical Fundamentals Summary

How do Jia Jie Biomedical's earnings and revenue compare to its market cap?
4109 fundamental statistics
Market CapNT$1.17b
Earnings (TTM)-NT$8.27m
Revenue (TTM)NT$237.07m

5.0x

P/S Ratio

-141.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4109 income statement (TTM)
RevenueNT$237.07m
Cost of RevenueNT$169.75m
Gross ProfitNT$67.33m
ExpensesNT$75.60m
Earnings-NT$8.27m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin28.40%
Net Profit Margin-3.49%
Debt/Equity Ratio0%

How did 4109 perform over the long term?

See historical performance and comparison

Valuation

Is Jia Jie Biomedical undervalued compared to its fair value and its price relative to the market?

1.3x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4109's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4109's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4109 is unprofitable, so we can't compare its PE Ratio to the TW Personal Products industry average.

PE vs Market: 4109 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4109's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4109 is good value based on its PB Ratio (1.3x) compared to the TW Personal Products industry average (2x).


Future Growth

How is Jia Jie Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jia Jie Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Jia Jie Biomedical performed over the past 5 years?

6.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4109 is currently unprofitable.

Growing Profit Margin: 4109 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 4109 is unprofitable, but has reduced losses over the past 5 years at a rate of 6.1% per year.

Accelerating Growth: Unable to compare 4109's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4109 is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (17.9%).


Return on Equity

High ROE: 4109 has a negative Return on Equity (-0.94%), as it is currently unprofitable.


Financial Health

How is Jia Jie Biomedical's financial position?


Financial Position Analysis

Short Term Liabilities: 4109's short term assets (NT$360.3M) exceed its short term liabilities (NT$61.4M).

Long Term Liabilities: 4109's short term assets (NT$360.3M) exceed its long term liabilities (NT$2.1M).


Debt to Equity History and Analysis

Debt Level: 4109 is debt free.

Reducing Debt: 4109 has no debt compared to 5 years ago when its debt to equity ratio was 47.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 4109 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 4109 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 59.7% per year.


Dividend

What is Jia Jie Biomedical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4109's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4109's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4109's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4109's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 4109 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4109's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Jia Jie Biomedical has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29%.


Top Shareholders

Company Information

Jia Jie Biomedical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Jia Jie Biomedical Co., Ltd.
  • Ticker: 4109
  • Exchange: TPEX
  • Founded: 1995
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$1.174b
  • Shares outstanding: 88.94m
  • Website: https://www.jiajiebio.com

Location

  • Jia Jie Biomedical Co., Ltd.
  • No. 61, Jiuru 1st Road
  • 3rd Floor
  • Kaohsiung
  • 807
  • Taiwan

Listings


Biography

Jia Jie Biomedical Co., Ltd. engages in the soft-shelled turtle food processing, manufacturing, sales, and trading business. It is also involved in the dairy products manufacturing, miscellaneous food manu...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 08:32
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.